Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00057213 · ClinicalTrials.gov registry record · Phase 2

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Phase 2 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
367
Enrollment target

NCT00057213: Completed Phase 2 study, sponsored by GlaxoSmithKline.

NCT00057213 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 367 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (176% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00057213, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
367 participants
Enrollment target

Study Summary

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

Interventions

  • DRUG Radafaxine

Trial Details

FieldValue
Enrollment Target 367 participants
Start Date 2003-03
Est. Completion 2007-04
Phase Phase 2
GlaxoSmithKline

1,345 total trials

What the finished NCT00057213 record still lists

NCT00057213 is an interventional study that assigns participants to a tested intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (176% higher).

The record links to 0 conditions, and to 1 intervention - of which Radafaxine is the first listed.

NCT00057213 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00057213 about?

NCT00057213 is a clinical study titled "An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder". A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

What is the current status of trial NCT00057213?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 367 participants. The study started on 2003-03. Estimated completion is 2007-04.

What interventions are being tested in trial NCT00057213?

The interventions under investigation include: Radafaxine (DRUG).

Who is sponsoring clinical trial NCT00057213?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00057213's enrollment target sits among peer trials

367 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04675476 · 368 participants · NA

    A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening

  • NCT05215353 · 368 participants · Phase 4

    A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors

  • NCT06182397 · 368 participants · NA

    Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

  • NCT06629610 · 368 participants · NA

    Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00057213, the US trial registry maintained by the National Library of Medicine. NCT00057213 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.